Manzoni Paolo, Baraldi Eugenio, Midulla Fabio, Claris Olivier, Dessardo Sandro, Heikkinen Terho, Thwaites Richard, Paes Bosco, Carbonell-Estrany Xavier, Dobryanskyy Dmytro, Cetinkaya Merih, Al Harbi Adel S, Kang Ji-Man, Goh Eng Neo Anne, Chi Hsin, Sant'Anna Guilherme, Villa Guillén Mónica, Mariani Gonzalo Luis, Safadi Marco Aurelio Palazzi, Urzua Soledad, Zar Heather J, Goussard Pierre, Rodgers-Gray Barry, Waghorne Nicola, Sanchez Luna Manuel
Department of Public Health and Pediatric Sciences, University of Torino School of Medicine, Turin, Piedmont, Italy.
Division of Paediatrics and Neonatology, Degli Infermi Hospital, Ponderano, Italy.
Open Forum Infect Dis. 2025 Jul 2;12(7):ofaf396. doi: 10.1093/ofid/ofaf396. eCollection 2025 Jul.
Long-acting monoclonal antibodies (LAmAbs) could dramatically reduce the respiratory syncytial virus (RSV) disease burden in children if implemented using clear, evidence-based recommendations.
The ARMADA Taskforce-an international, multidisciplinary expert panel-undertook a systematic review to develop LAmAbs consensus recommendations for RSV disease prevention in children.
The Taskforce recommends LAmAbs for all infants aged <8 months in the absence of maternal RSV vaccination, preterm infants (<37 weeks' gestational age) aged <12 months, and children <24 months with high-risk conditions. Seasonal LAmAb administration is recommended, although in RSV-endemic countries decisions should be made locally concerning administration year-round or with peak RSV incidences.
The Taskforce strongly endorses LAmAbs implementation based on their efficacy, effectiveness, and public health impact. These recommendations provide a blueprint to inform guidelines worldwide. Wider equitable access to LAmAbs at affordable prices, especially in low- and middle-income countries is needed to reduce the childhood RSV burden.
如果按照明确的循证建议使用长效单克隆抗体（LAmAbs），可显著减轻儿童呼吸道合胞病毒（RSV）疾病负担。
“舰队行动小组”（ARMADA Taskforce）——一个国际多学科专家小组——进行了一项系统评价，以制定关于预防儿童RSV疾病的LAmAbs共识建议。
该行动小组建议，对于母亲未接种RSV疫苗的所有8月龄以下婴儿、胎龄小于37周的12月龄以下早产儿以及患有高危疾病的24月龄以下儿童，均应使用LAmAbs。建议季节性使用LAmAbs，不过在RSV地方性流行国家，应根据当地情况决定全年用药还是在RSV发病高峰时用药。
该行动小组基于LAmAbs的疗效、有效性和对公共卫生的影响，强烈支持其应用。这些建议为全球制定指南提供了蓝本。需要以可承受的价格更广泛、公平地获取LAmAbs，尤其是在低收入和中等收入国家，以减轻儿童RSV疾病负担。
